There is increasing evidence that deregulation of gene expression at the level of mRNA translation can contribute to cell transformation and the malignant phenotype. Two steps in the pathway of polypeptide chain initiation, viz. the assembly of the 43S initiation complex catalysed by polypeptide chain initiation factor eIF2 and the binding of eIF4E to eIF4G during the recruitment of mRNA to the ribosome, have been shown to be likely targets for changes associated with tumorigenesis. The activity of eIF2 is controlled by changes in phosphorylation of the a subunit of this factor. The availability of eIF4E for binding to eIF4G is regulated by the phosphorylation of a small family of eIF4E-binding proteins (the 4E-BPs). The activities of the protein kinases and/or phosphatases responsible for the (de)phosphorylation of these substrates may in turn be controlled by cellular and viral oncogenes and tumour-suppressor genes. This review will describe recent aspects of the mechanisms involved, with particular emphasis on the regulation of the eIF2a kinase PKR and the control of 4E-BP phosphorylation by viral gene products, growthinhibitory cytokines and the tumour-suppressor protein p53.
Introduction
Eukaryotic cells possess a variety of means by which they are able to regulate the expression of the genes they contain. These mechanisms include control at the level of transcription, differential splicing, regulation of the nuclear export of transcripts, modulation of mRNA stability and changes in the rates of translation of specific mRNAs. Although transcriptional regulation is obviously crucial, the control of gene expression also relies heavily on translational selectivity and the mechanism of protein synthesis provides the cell with a variety of sophisticated and subtle means to modulate the rates of production of key proteins, independently of events in the nucleus.
Translational control and cancer
In view of the fact that cell transformation to a tumorigenic phenotype stems from a series of genetically regulated events, it is not surprising that translational control plays a role in the process (Clemens and Bommer, 1999) . Although dysregulated transcription constitutes a mechanistic basis for many types of cancer, the overproduction of potentially oncogenic proteins that stimulate cell proliferation or inhibit apoptosis, or the underproduction of factors involved in tumour suppression, can also arise from changes within the machinery of protein synthesis (Rosenwald, 1996a) .
Two stages in the process of initiation of protein synthesis are particularly implicated in cell transformation ( Figure 1 ). These are: (1) the binding of GTP to initiation factor eIF2, a prerequisite for the assembly of the 43S initiation complex; and (2) the association of the cap-binding factor eIF4E with the large scaffold protein eIF4G, a step necessary for the subsequent recruitment of mRNA to the ribosome. It is likely that either step can be rate-limiting for overall translation under various circumstances; moreover, the translation of individual mRNA species can be differentially regulated at these two levels, depending on the structure of the mRNA in question (Graff et al., 1997; Clemens and Bommer, 1999; Meijer and Thomas, 2002; Graff and Zimmer, 2003) . The possibility that eIF2-and eIF4E-dependent stages in protein synthesis may be important in the regulation of cell growth or cell death is suggested by observations that one or both of these initiation factors are often overexpressed in tumours such as bronchioalveolar carcinoma of the lung , thyroid carcinoma or non-Hodgkin's lymphoma , as well as in several other types of cancer cell.
Initiation factor eIF2
As shown in Figure 1 , eIF2 forms a ternary complex with GTP and Met-tRNA f and places the latter on the 40S ribosomal subunit prior to the mRNA-binding step in translation. At a later stage in the initiation process, the GTP is hydrolysed to GDP, which then remains bound to the eIF2 after the latter is released from the ribosome. GDP has a high affinity for eIF2 under physiological conditions and has to be exchanged for a new molecule of GTP through the action of the guanine nucleotide exchange factor eIF2B. Phosphorylation of eIF2 at position Ser 51 of its smallest (a) subunit converts this factor from a substrate into an inhibitor of eIF2B and results in the accumulation of 'dead end .GDP] complexes (Clemens, 2001 ). As eIF2 is usually more abundant than eIF2B in cells only partial phosphorylation of eIF2a is sufficient to inhibit most of the eIF2B activity. Phosphorylation of eIF2a at Ser 51 can be accomplished by a small family of protein kinases that respond to various physiological cell stresses (Clemens, 2001) . Of these enzymes, probably the most significant in relation to malignant transformation is the interferon-inducible kinase PKR (see below).
Although unphosphorylated eIF2 is essential for the initiation of protein synthesis, it does not necessarily follow that the inability of a cell to phosphorylate the factor contributes to the dysregulation of growth control. Nevertheless, it has been demonstrated that expression of a nonphosphorylatable form of eIF2a, in which Ser 51 has been converted to Ala, can inhibit apoptosis (Srivastava et al., 1998) and cause malignant transformation of NIH 3T3 cells (Donze et al., 1995) .
The levels of eIF2 are often higher in tumour cells than in their normal counterparts (Rosenwald et al., 1993; Rosenwald, 1996b; Lobo et al., 2000) , although this could of course be an effect rather than a cause of the differences in growth regulation between these tissues. Surprisingly, one study has reported that the ratio of phosphorylated to unphosphorylated eIF2a is higher in various gastrointestinal neoplasms than in the corresponding untransformed tissues (Lobo et al., 2000) . One explanation for this is that tumour cells may be able to tolerate elevated phosphorylation of eIF2a because they may have increased amounts of eIF2B and are therefore less sensitive to the inhibitory effects of Ser 51 phosphorylation.
The protein kinase PKR
PKR is an interferon-inducible eIF2a kinase that binds to double-stranded RNA (dsRNA) and then undergoes autophosphorylation at several sites, resulting in its activation. An additional dsRNA-independent mechanism of activation of this enzyme is mediated by the protein PACT (Patel and Sen, 1998) . Important roles in both the regulation of protein synthesis and the control of cell growth and survival have been demonstrated for PKR (Clemens and Elia, 1997; Williams, 1999 ; Clemens, Figure 1 The pathway of initiation of protein synthesis and targets for regulation by oncogenic and antioncogenic factors. The 43S preinitiation complex is assembled by association of the [Met-tRNA f .eIF2.GTP] ternary complex with the 40S ribosomal subunit (to which initiation factors eIF1A and eIF3 are already bound). This step is followed by the binding of mRNA to form a 48S preinitiation complex, a process that usually requires initiation factors eIF4E, 4G, 4A and 4B. The role of eIF4E is to bind the 5 0 cap structure on the mRNA and to associate with eIF4G. The latter also binds to eIF3, thus forming a bridge between the mRNA and the 40S ribosomal subunit. Addition of the 60S ribosomal subunit, in a step requiring initiation factor eIF5, results in hydrolysis of the GTP associated with the eIF2 and loss of eIF3 from the ribosome. The 80S initiation complex thus formed is then competent to begin protein synthesis. Before eIF2 can be reutilized for another round of initiation the GDP bound to it must be exchanged for a new molecule of GTP, in a reaction catalysed by eIF2B. Phosphorylation of eIF2 on its a subunit (position Ser 51 ) blocks this exchange process and leads to the formation of a stable and inactive [eIF2.GDP.eIF2B] complex. In this figure, the two key steps in the control of initiation are indicated by heavy arrows and the factors that are known targets for regulation in cell transformation are shown in red 2001). Several studies have established that activation of PKR can either induce apoptotic cell death or at least enhance this process when it is initiated by other agents (Der et al., 1997; Balachandran et al., 1998; Srivastava et al., 1998; Vorburger et al., 2002) . Conversely, in cells that are deficient for the kinase or contain a dominantnegative (DN) form, there is substantial resistance to apoptosis (Der et al., 1997; Balachandran et al., 1998; Srivastava et al., 1998; Gil and Esteban, 2000) . It is not clear whether the phosphorylation of eIF2a is sufficient to mediate the proapoptotic effects of PKR since the kinase has a number of other potential substrates (e.g. Parker et al., 2001) , and DN PKR mutants may acquire a gain of function that leads to interference with other dsRNA-regulated pathways (Raveh et al., 1996) . Nevertheless, expression of an inhibitor of eIF2a phosphorylation or of the nonphosphorylatable eIF2a S51A mutant does partially protect cells from apoptosis (Srivastava et al., 1998) .
On the other hand, there is evidence that PKR may also contribute to positive growth regulation since fibroblasts from PKR knockout mice grow more slowly and show defects in cell cycle progression (ZamanianDaryoush et al., 1999) . PKR is also required for PDGF signalling (Deb et al., 2001) . Thus, the protein kinase may be required for normal cell proliferation, and also contribute to apoptosis when overexpressed or aberrantly activated, as is the case for certain other key regulatory molecules such as c-Myc (Packham et al., 1996; Evan and Littlewood, 1998; Prendergast, 1999) .
PKR and cancer
A number of pieces of evidence point to a role for PKR in cancer (reviewed in Jagus et al., 1999) . One copy of the gene for this protein is rearranged in a murine lymphocytic leukaemia (Abraham et al., 1998) , although it is not clear whether this mutation contributes to the phenotype of the tumour. More compelling is the fact that certain DN PKR mutants cause tumorigenic transformation of murine fibroblasts (Meurs et al., 1993; Barber et al., 1995) . Several years ago, this led to the proposal that PKR is the product of a tumoursuppressor gene. Such a possibility provided a potential explanation for the antitumour activity of interferons (albeit in a limited range of cancers), since PKR is induced by interferon treatment (Clemens, 1992) . More recently, however, the role of PKR as a tumour suppressor has been questioned by results showing elevated levels and/or activity of the kinase in some breast cancers, melanomas and colon tumours, and in cell lines derived from them (Haines et al., 1996; Kim et al., 2000 Kim et al., , 2002 Nussbaum et al., 2003) (although one study found that the PKR in breast carcinoma was inactive, possibly due to a transdominant inhibitor (Savinova et al., 1999) ).
There has been controversy as to whether the tumorigenic effects of DN PKR mutants are due to sequestration of PKR activators such as dsRNA or are caused by heterodimerization between wild-type and DN forms of the protein kinase (Clemens and Elia, 1997) . The former mechanism is supported by the fact that other dsRNA-binding proteins can also cause cell transformation (Garcia et al., 2002) . However, several of these also bind to PKR. Some of the effects of dsRNA on cell growth or survival have been shown to require PKR activity, in some cases involving changes in the expression of known mitogenic or antiapoptotic factors such as IGF-I (Chacko and Adamo, 2002), but the mechanisms underlying these events are not known.
PKR and the regulation of translation by the tumour necrosis factor (TNF) family
Members of the TNF family inhibit growth and induce programmed cell death in many cell types, and PKR has been implicated in mediating some of these effects. The actions of TNFa-related apoptosis-inducing ligand (TRAIL) are of particular interest for cancer therapy since this agent acts preferentially on tumour cells (Ashkenazi et al., 1999; Walczak et al., 1999) . Association of TNFa and TRAIL with their respective cell surface receptors results in the recruitment of adaptor proteins such as TRADD (TNFR1-associated death domain protein) and FADD (Fas-associated death domain protein) to form a death-inducing signalling complex (DISC) (Baud and Karin, 2001 ). TRADD and FADD in turn recruit procaspase-8 and/or procaspase-10, the proteolytic activation of which leads to the activation of effector caspases (Budihardjo et al., 1999; Baud and Karin, 2001) . The relationships of these events to the mechanisms by which translation is regulated are not yet fully established. There is a marked increase in eIF2a phosphorylation in MCF-7 cells and fibroblasts following TNFa or TRAIL treatment. In contrast, eIF2a does not become more phosphorylated and protein synthesis is not inhibited following treatment of PKR knockout cells with TNFa .
The activation of caspase-8 and downstream apoptosis also fails to occur in response to TNFa in PKRÀ/À cells. However, the link between the PKR requirement for caspase-8 activation and for the inhibition of translation is not yet resolved. It is unlikely that PKR is itself a component of the DISC complex since twohybrid studies have failed to show any interaction between the kinase and proteins such as FADD, TRADD, RIP (receptor-interacting protein) or procaspase-8 (X Saelens, personal communication). Expression of components of the DISC may be depressed in cells containing DN PKR (Balachandran et al., 1998 (Balachandran et al., , 2000 ; however, it appears that TNF receptor signalling per se can remain at least partially functional in the absence of the kinase since the transcription factor NFkB could still be activated by TNFa in PKRÀ/À cells (Der et al., 1997) . It has not been determined whether assembly of the DISC in response to the binding of TNFa or TRAIL to their respective receptors is defective in DN PKR or PKRÀ/À cells. Recent evidence also indicates that PKR is itself a target for caspase-dependent cleavage and that such cleavage can result in the activation of the protein kinase independently of stimulation by dsRNA (Saelens et al., 2001) . This finding suggests a mechanism of PKR-mediated positive feedback for the inhibition of protein synthesis following exposure of cells to members of the TNF family.
PKR as a target for oncogenic viruses
As PKR has a major role to play in mediating the antiviral effects of the interferons, as well as regulating cell growth and survival, it is not surprising that many viruses have evolved strategies to block or evade the inhibition of protein synthesis by the protein kinase. This is also the case for some viruses implicated in cellular transformation, making such phenomena of particular relevance to cancer. Thus, both Epstein-Barr virus (EBV), which is strongly associated with Burkitt's lymphoma, nasopharyngeal carcinoma and malignancies arising in immunocompromised individuals (Young and Murray, 2003) and hepatitis C virus (HCV), which is a major risk factor for hepatocellular carcinoma (Kiyosawa et al., 1998) , express gene products that interfere with the activation of PKR.
In the case of EBV, the small virus-encoded RNAs EBER-1 and EBER-2 bind to PKR and one or both can block the activation of the enzyme by dsRNA (Sharp et al., 1993) . Moreover, cells expressing these RNAs show phenotypic changes consistent with dysregulation of growth or even full malignant transformation (Komano et al., 1999; Ruf et al., 2000; Yamamoto et al., 2000; Laing et al., 2002) . This may be due to the ability of these RNAs to block the proapoptotic effects of PKR, since EBER expression confers resistance to interferon-induced cell death in EBV-negative Burkitt's lymphoma cell lines (Nanbo et al., 2002) .
HCV possesses more than one potential strategy for inhibiting PKR. Both the viral nonstructural protein NS5A and the viral envelope protein E2 have been shown to be capable of inhibiting the activity of the protein kinase, albeit through different mechanisms (Taylor et al., 2000) . In addition, recent evidence points to a role as a potential PKR inhibitory element for the highly structured 5 0 untranslated region of HCV RNA, which also serves as an internal ribosome entry site for translation (Vyas et al., 2003) . In this case, this RNA may function in a manner similar to the EBERs of EBV, competing with dsRNA for binding to PKR and thereby preventing the autophosphorylation and activation of the enzyme.
In neither case, is it clear whether the inhibition of PKR is sufficient to confer transforming ability to EBV or HCV, and indeed these viruses almost certainly possess additional tumorigenic mechanisms (especially in the case of EBV (Young and Murray, 2003) ). Nevertheless, the ability to block the activation of a protein kinase that is otherwise proapoptotic and can itself be tumorigenic when expressed in a DN form strongly suggests that inhibition of PKR is an important property of these tumour-promoting viruses.
Initiation factors eIF4E and eIF4G and the eIF4E-binding proteins
Although the ability to bind the initiator Met-tRNA f to the ribosome, catalysed by eIF2, is clearly important for the initiation of a new polypeptide chain, the recruitment of an mRNA molecule to the initiation complex is obviously also essential. The latter step requires both eIF4E (to bind to the 5 0 cap structure of the mRNA) and eIF4G (to act as a scaffold protein that brings the [eIF4E.mRNA] complex to the ribosome by interacting with another ribosome-bound factor, eIF3 (Figure 1) . Initiation factors eIF4E and eIF4G interact with each other (together with eIF4A) to form the eIF4F complex, but the relative abundance of eIF4E and eIF4G has been the subject of considerable controversy. Earlier studies suggested that eIF4E was rate-limiting for protein synthesis (Sonenberg, 1994) , whereas this factor may, in fact, be relatively abundant in the cell (Rau et al., 1996) and probably present in considerable molar excess over eIF4G (von der Haar and McCarthy, 2002) . However, the availability of eIF4E in a functional form can be strongly limited by its association with a small family of abundant inhibitory eIF4E-binding proteins, the 4E-BPs (Gingras et al., 1999b) . This association is in turn controlled by the state of phosphorylation (at multiple sites) of these 4E-BPs (Figure 2 ).
eIF4E, eIF4G and cancer
Many publications have documented the overexpression of eIF4E in various kinds of tumours (reviewed in Zimmer et al., 2000) . Most of these studies were unable to distinguish cause from effect in this correlation. However, experimental overexpression of eIF4E can also cause malignant transformation and, conversely, high-level expression of the best-studied eIF4E-binding protein, 4E-BP1, inhibits cell growth and promotes apoptosis Jiang et al., 2003) . In addition, there are some indications that the level of eIF4G expression may also correlate with a tumorigenic phenotype. The factor is overexpressed, probably as a result of gene amplification, in some squamous cell lung carcinomas (Brass et al., 1997; Bauer et al., 2001 ) and experimental overproduction of eIF4G has been linked with cell transformation (Fukuchi-Shimogori et al., 1997) . Taking all these factors into account, it would seem likely that the balance between the amount of available eIF4E (determined by the molar ratio of eIF4E to 4E-BPs and by the state of phosphorylation of the latter) and the amount of eIF4G in a cell can have significant effects on cellular phenotype. How such effects are achieved remains to be established, but a likely mechanism is that high levels of eIF4E and/or eIF4G drive the formation of greater amounts of eIF4F and that this complex in turn increases the efficiency with which 'difficult' mRNAs (e.g. those with extensive 5 0 secondary structure) are translated. Many mRNAs with important roles in the control of cell growth or apoptosis have long and structurally complex 5 0 untranslated regions (Kozak, 1991a, b) and may require high levels of eIF4F for their translation. Candidate mRNAs with critical roles in growth or cell survival regulation that may be influenced by eIF4E levels include the src family member lck (Marth et al., 1988) , c-Myc (Carter et al., 1999) , cyclin D1 and VEGF (Chung et al., 2002) . As eIF4E availability is controlled by the 4E-BPs, conditions leading to increased 4E-BP phosphorylation and thus dissociation of the [eIF4E.4E-BP] complex (Figure 2) will have the same effect as increased expression of eIF4E itself. An example of this is seen in the influence of integrin a6b4 on VEGF expression in breast carcinoma (Chung et al., 2002) . In the opposite sense, expression of constitutively active (nonphosphorylatable) 4E-BP1 enhances the expression of the cyclin-dependent kinase inhibitor p27Kip1 at a post-transcriptional level, probably because the mRNA encoding p27Kip1 is translated by an eIF4E-independent mechanism (Jiang et al., 2003) .
Regulation of the 4E-BPs
Numerous examples now exist of physiological stresses and other growth-regulatory conditions that affect the state of phosphorylation of the 4E-BPs at multiple sites. The nature of such regulation, as well as the protein kinase systems involved, have been described in detail in several recent articles and reviews (Gingras et al., 1999a (Gingras et al., , 2001a Raught et al., 2001) . Prominent among the possible pathways involved in promoting 4E-BP phosphorylation is the rapamycin-sensitive enzyme mTOR, but recent evidence suggests that other, rapamycininsensitive, kinases such as pim-2 may also play a role (Fox et al., 2003) . There is also evidence that the levels of 4E-BPs may change with differing physiological circumstances. For example, in sea urchin eggs, 4E-BP is rapidly destroyed following fertilization (Salau¨n et al., 2003) and, conversely, the level of mammalian 4E-BP1 increases rapidly when breast cancer cells are treated with the proapoptotic cytokine TRAIL (I Jeffrey and MJ Clemens, unpublished data). These more recent data suggest that, to be successful, any anticancer strategy targeted at the 4E-BPs (e.g. inhibition of mTOR activity by rapamycin (Hidalgo and Rowinsky, 2000) ) might also have to inhibit other protein kinase-mediated phosphorylation events affecting these proteins, as well as possibly preventing the downregulation of 4E-BP protein levels.
Regulation of apoptosis by the 4E-BPs
Whereas overexpression of eIF4E may contribute to tumorigenesis by inhibiting apoptosis (Polunovsky et al., 1996; Li et al., 2003) , enhanced expression or activity of the 4E-BPs promotes cell death. Thus, for example, in Ras-transformed cells enforced expression of 4E-BP1 sensitizes the cells to apoptosis induced by cytostatic drugs by a mechanism that is dependent on the ability of the 4E-BP to sequester eIF4E . This suggests either that the synthesis of antiapoptotic proteins has an unusually strong requirement for eIF4E or that the synthesis of proapoptotic proteins is relatively independent of this protein (perhaps because of a lack of requirement for a 5 0 cap structure by the relevant mRNAs). There is a difference in sensitivity between transformed and normal cells in this respect, with the latter requiring a greater level of suppression of eIF4E by 4E-BP1 before apoptosis is triggered (Li et al., Figure 2 Control of the availability of eIF4E by the 4E-BPs. Initiation factor eIF4E forms a complex with eIF4G and eIF4A (to produce the complex known as eIF4F). The eIF4E binds to the 5 0 cap structure of mRNA, whereas the eIF4G binds to ribosomeassociated eIF3 (see Figure 1) . The association of eIF4E with eIF4G is inhibited by the 4E-BPs, which in their unphosphorylated state are competitive inhibitors of eIF4G binding. Phosphorylation of the 4E-BPs relieves this inhibition by blocking the binding of these proteins to eIF4E. Phosphorylation occurs on multiple sites and is catalysed by protein kinases that are regulated by the rapamycinsensitive protein kinase mTOR (Gingras et al., 2001b; Raught et al., 2001 ) and the rapamycin-insensitive enzyme pim-2 (Fox et al., 2003) . Protein phosphatases that act on the 4E-BPs may also be regulated by these and other pathways 2002). This may be because malignant transformation is associated with an increased requirement for capdependent translation, relative to the situation in normal cells. Such a requirement may, in turn, reflect the need for translation of mRNAs with highly structured 5 0 UTRs that encode proteins essential to the tumourigenic phenotype.
Since 4E-BP phosphorylation is governed, at least in part, by the activity of mTOR, and the latter is under the control of the phosphatidylinositol 3-kinase (PI3 K)-protein kinase B (Akt) pathway (Gingras et al., 2001b; Raught et al., 2001) , regulation of 4E-BP activity may provide a further mechanism by which Akt exerts its antiapoptotic effects (Nicholson and Anderson, 2002) . Moreover, the ability of rapamycin to inhibit mTOR and thus the phosphorylation of the 4E-BPs could explain the proapoptotic effects of this drug, as well as the ability to block transformation by agents such as EGF (Nomura et al., 2003) . The levels of 4E-BPs in cells can influence cellular sensitivity to rapamycin (Dilling et al., 2002) . However, both Akt and mTOR are involved in additional regulatory pathways and caution is needed in coming to the conclusion that the 4E-BPs are the most important targets in mediating the proapoptotic effects of rapamycin. Furthermore, the importance of the dephosphorylation of the 4E-BPs, relative to that of the phosphorylation of eIF2a, in the regulation of translation by inducers of apoptosis is not yet clear .
Effects of growth factors and cytokines on the eIF4E/4E-BP system
Previous studies using Jurkat lymphoma and MCF-7 breast cancer cell lines have shown that cytokines with a negative effect on cell growth or survival also have an impact on the eIF4E/4E-BP system. Members of the TNF family (TNFa, TRAIL and Fas ligand) inhibit overall translation by a mechanism that is characterized by decreased phosphorylation of 4E-BP1 and increased association of eIF4E with 4E-BP1, as well as other regulatory changes Jeffrey et al., 2002) . TNFa, TRAIL and Fas ligand also induce apoptosis in these systems and it is of interest that, although the changes in the protein synthetic machinery precede the development of overt cell death or even loss of viability, the effects of TRAIL on 4E-BP1 (as well as overall translation) are dependent on caspase activity . Recent data also suggest that TRAIL either enhances the synthesis or decreases the rate of turnover of 4E-BP1 in MCF-7 cells (IW Jeffrey and MJ Clemens, unpublished data), thus providing a further link between this cytokine and the 4E-BP system.
Regulation of translation by p53
The tumour-suppressor protein p53 acts as a key regulator of both cell cycle progression and apoptosis. It functions primarily as a transcription factor that controls the expression of a wide range of genes regulating cell proliferation, DNA repair or cell survival (Tokino and Nakamura, 2000; Vousden, 2000; Appella, 2001; Ryan et al., 2001) . However, not all of the effects of p53 require the transcriptional transactivating function of this protein, and several reports have suggested that some of the activities of the tumour suppressor are independent of its effects in the cell nucleus (e.g. Caelles et al., 1994; Gao and Tsuchida, 1999; Marchenko et al., 2000; Kokontis et al., 2001; Mihara et al., 2003) . Evidence is now accumulating which demonstrates that p53 has marked effects on the control of protein synthesis. We have shown that activation of p53 rapidly inhibits overall translation by about 60-70% and that this effect is exerted at the level of polypeptide chain initiation (Horton et al., 2002) . The downregulation of translation is not simply a consequence of the inhibition of cell proliferation or loss of cell viability induced by p53 since it precedes these events by several hours (Constantinou et al., 2003) . Although we cannot exclude the possibility that transcriptional upregulation or downregulation of the expression of specific genes is required for the effects of p53 on overall protein synthesis (Figure 3) , the tumour-suppressor protein has been shown to regulate the translation of specific mRNAs, such as those encoding cdk4, FGF-2 and p53 Figure 3 Potential mechanisms for regulation of the availability of eIF4E by p53. Activation of p53 rapidly induces the dephosphorylation of the inhibitory eIF4E binding protein, 4E-BP1, resulting in an increase in the association of this protein with eIF4E and a corresponding decrease in the association of eIF4G with eIF4E (Horton et al., 2002) . It is not yet clear whether these effects are due to decreased protein kinase activity or increased protein phosphatase activity towards 4E-BP1. Nor is it known whether this regulation requires new p53-induced transcription or whether it is a direct cytoplasmic effect of the activation of the tumour-suppressor protein. In addition, activation of p53 induces specific proteolytic cleavage of eIF4G (not shown here) and this may further contribute to the reduction of complex formation between eIF4E and intact eIF4G (Constantinou et al., 2003) itself (Ewen et al., 1995; Mosner et al., 1995; Ewen and Miller, 1996; Miller et al., 2000; Galy et al., 2001a, b) .
Our recent studies on the mechanisms by which p53 modulates translational initiation have utilized an erythroleukaemia cell line that expresses a temperature-sensitive p53 mutant (Val 135 ). In this system, the rapid decrease in translation caused by activation of p53 at the permissive temperature (321C) is accompanied by dephosphorylation of 4E-BP1 within 2-4 h. This results in increased association of eIF4E with 4E-BP1 and decreased association of eIF4E with eIF4G (Horton et al., 2002) . Again these p53-induced effects precede the inhibition of cell proliferation and induction of apoptosis. Regulation of 4E-BP1 also occurs in cells exposed to DNA-damaging agents (Morley et al., 1998; Tee and Proud, 2000; Jeffrey et al., 2002) and in some cases this may also be due to the activation of p53 by these agents. However, DNA damaging drugs can regulate translation in p53-negative cells (Morley et al., 1998) .
The signalling pathways by which p53 exerts its effects on eIF4E/4E-BP1 are not yet established. Since p53 activation also causes inhibition of the activity of another target of mTOR, the ribosomal protein S6 kinase (p70S6k) (Horton et al., 2002) , it is possible that p53 may downregulate the activity of mTOR or an mTOR-related pathway. However, as Figure 2 illustrates, additional mechanisms involving other protein kinases and/or phosphatases that act on 4E-BP1 (and perhaps p70S6k) are also possible. Indeed, at present, our data favour a largely mTOR-independent mode of action for p53 on the translational machinery (Horton et al. (2002) and C Constantinou and MJ Clemens, unpublished data).
Conclusions
This review has indicated a number of pathways and mechanisms in the regulation of translation that may contribute to the changes in gene expression associated with malignant transformation. In some cases, such changes may be primary causes of the alterations in cellular phenotype that characterize various types of cancer; in other situations, they may represent the consequences of transforming events that occur at the nuclear level. What is becoming clear, however, is that agents that can limit the growth or viability of tumour cells, including cytokines of the TNF family and endogenous tumour-suppressor proteins such as p53, target the translational machinery as part of their mode of action. Improved knowledge of the molecular mechanisms by which these agents act on translation may facilitate the development of new strategies for cancer therapy, either to enhance the efficacy of existing treatments or to mimic the actions of the appropriate cytokines or tumour-suppressor proteins. In either case, restoration to normal of the regulation of translation may help to impair the growth and survival abilities of tumour cells.
